

Research: ProlImmune® and Glutathione

Find research results in this list of the most relevant published research relating to Immune Formulation 200®.

A novel antiviral inhibits Zika virus infection while increasing intracellular glutathione biosynthesis in distinct cell culture models.

<https://www.sciencedirect.com/science/article/pii/S0166354217306435>This off-site link opens in new tab or window.

Long-term supplementation with a cystine-based antioxidant delays loss of muscle mass in aging.

<https://pubmed.ncbi.nlm.nih.gov/23459206/>This off-site link opens in new tab or window.

Salutary effects of a novel oxidative stress modulator on adenine-induced chronic progressive tubulointerstitial nephropathy

<https://pubmed.ncbi.nlm.nih.gov/22937204/>This off-site link opens in new tab or window.

A novel cystine based antioxidant attenuates oxidative stress and hepatic steatosis in diet-induced obese mice

<https://pubmed.ncbi.nlm.nih.gov/21570964/>This off-site link opens in new tab or window.

Effects of a novel cystine-based glutathione precursor on oxidative stress in vascular smooth muscle cells

<https://pubmed.ncbi.nlm.nih.gov/20592243/>This off-site link opens in new tab or window.

Inhibition of apoptotic signalling in spermine-treated vascular smooth muscle cells by a novel glutathione precursor

<https://pubmed.ncbi.nlm.nih.gov/20121705/>

Research and Charity

Contribution to Research and Charity

The potential for Immune Formulation 200® to impact the body's ability to produce glutathione on an intracellular level has become the subject of a License donation to the Program Directors Association of Research Centers in Minority Institutions (RCMI). RCMI, a consortium of 18 medical research institutions, has committed \$17.5M annually, funded by the National Institutes of Health (NIH), after their initial study of ProlImmune®, to research and conduct clinical studies on oxidative stress, and ProlImmune®'s influence on various aspects of health including aging. The contract is for five (5) years and a total of \$87,500,000.00.

Drew University of Medicine and Science in partnership with a team from the Laboratory of the David Geffen School of Medicine UCLA reported the results of its first study at a meeting of the American Federation for Medical Research in Carmel, CA, February 2008

~~~~~  
***RCMI has committed \$17.5 million/year for research to study, learn, understand and define the effectiveness of Immune Formulation 200® in increasing bodily Glutathione levels.***  
~~~~~

This commitment underscores the medical research community's belief in the revolutionary potential of the antioxidant benefits to be derived from Immune Formulation 200®.

In addition, in their commitment, RCMI underscores their interest with the economic dimension this discovery could provide.

Dr. Crum has donated the five Licenses for Immune Formation 200® to RCMI to facilitate this important, far reaching immune support research.